Quick Answer
Sarepta Therapeutics, Inc. reported Total Assets of $3.35 billion for the year ending 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -15.5% in Total Assets from 2024 to 2025.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $74.93 million | Q3 2011: $61.08 million | Q1 2012: $46.65 million | Q2 2012: $42.10 million | Q3 2012: $53.08 million | Q1 2013: $193.34 million | Q2 2013: $183.63 million | Q3 2013: $304.48 million | Q1 2014: $275.39 million | Q2 2014: $337.31 million | Q3 2014: $319.06 million | Q1 2015: $242.71 million | Q2 2015: $231.71 million | Q3 2015: $184.75 million | Q1 2016: $213.36 million | Q2 2016: $204.07 million | Q3 2016: $487.31 million | Q1 2017: $511.53 million | Q2 2017: $450.14 million | Q3 2017: $800.28 million | Q1 2018: $1.30 billion | Q2 2018: $1.25 billion | Q3 2018: $1.18 billion | Q1 2019: $1.96 billion | Q2 2019: $1.75 billion | Q3 2019: $1.70 billion | Q1 2020: $2.95 billion | Q2 2020: $2.88 billion | Q3 2020: $2.78 billion | Q1 2021: $2.77 billion | Q2 2021: $2.76 billion | Q3 2021: $2.66 billion | Q1 2022: $3.06 billion | Q2 2022: $3.00 billion | Q3 2022: $3.16 billion | Q1 2023: $3.06 billion | Q2 2023: $3.13 billion | Q3 2023: $3.11 billion | Q1 2024: $3.22 billion | Q2 2024: $3.42 billion | Q3 2024: $3.60 billion | Q1 2025: $3.47 billion | Q2 2025: $3.68 billion | Q3 2025: $3.49 billion.
- Over the full 16 years of available data (2010 to 2025), Sarepta Therapeutics, Inc.'s Total Assets has grown by 7,185.8%.
- Historical annual values: Fiscal year 2025: $3.35 billion | Fiscal year 2024: $3.96 billion | Fiscal year 2023: $3.26 billion | Fiscal year 2022: $3.13 billion | Fiscal year 2021: $3.15 billion | Fiscal year 2020: $2.98 billion | Fiscal year 2019: $1.82 billion | Fiscal year 2018: $1.64 billion | Fiscal year 2017: $1.31 billion | Fiscal year 2016: $424.10 million | Fiscal year 2015: $273.78 million | Fiscal year 2014: $295.03 million | Fiscal year 2013: $291.57 million | Fiscal year 2012: $204.99 million | Fiscal year 2011: $54.37 million | Fiscal year 2010: $45.98 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: